Infectious Disease

Found 15 technologies within Infectious Disease RSS ATOM

Chimeric Dengue Vaccine

19-0125 – Mosquito-borne Dengue Virus (DENV) is a major global public health concern with ~400 million new cases of DENV infections annually. There are four serotypes of DENV and exposure to one serotype does not guarantee immunity from infection by the other three serotypes. This is a significant problem as previous DENV infection puts individuals at an increased risk of developing hemorrhagic fever... Read More

2/4 Dengue Chimeric Vaccine

17-0116 – Mosquito-borne Dengue Virus (DENV) is a major global public health concern with ~400 million new cases of DENV infections annually. There are four serotypes of DENV and exposure to one serotype does not guarantee immunity from infection by the other three serotypes. This is a significant problem as previous DENV infection puts individuals at an increased risk of developing hemorrhagic fever... Read More

1/2 Chimeric Dengue Vaccine

14-0002 – Mosquito-borne Dengue Virus (DENV) is a major global public health concern with ~400 million new cases of DENV infections annually. There are four serotypes of DENV and exposure to one serotype does not guarantee immunity from infection by the other three serotypes. This is a significant problem as previous DENV infection puts individuals at an increased risk of developing hemorrhagic fever... Read More

Dengue Vaccine

12-0090 – Mosquito-borne Dengue Virus (DENV) is a major global public health concern with ~400 million new cases of DENV infections annually. There are four serotypes of DENV and exposure to one serotype does not guarantee immunity from infection by the other three serotypes. This is a significant problem as previous DENV infection puts individuals at an increased risk of developing hemorrhagic fever... Read More

Subunit Vaccine Against Dengue Virus

20-0009 – Current approaches to Dengue Virus (DENV) vaccine design all make use of live attenuated viruses. This appraoch suffers from difficulties in desinging a vaccine formulation that can eleicit a balanced immune response against all four serotypes of DENV. Subunit vaccines, composed only of the immungenic E protein found on the surface of the DENV viral capsid, present an alternative appraoch to... Read More

Ultrasound Mediated Delivery of Therapeutics and Disruption of Drug Resistant Biofilms

20-0102 – Background Biofilms are aggregates of microorganisms embedded in a self-produced extracellular matrix and can attach to each other or to surfaces, including a patient’s skin or soft tissue, or an implanted medical device, such as a catheter. Microorganisms that make up biofilms can include bacteria, fungi, and protists. Biofilms are prevalent in many infections and are resistant to... Read More

Use of Aminobisphosphonates as Latency Reversing Agents

18-0151 – Novel methods for the reversal of latency in HIV infected cells, and for the clearance of latently infected cells have been discovered. Aminobisphosphonates (N-BPs) are a class of drug currently FDA approved for the treatment of several diseases involving the loss of bone density. Our investigators have demonstrated that N-BPs can reverse latent HIV viruses in infected immune cells without... Read More

Epitope and Antibody for Prevention of Zika and Dengue Viruses

17-0061 – An epitope that can elicit broadly neutralizing antibodies against Zika virus (ZIKV) and dengue virus (DENZ) has been developed. ZIKV and DENV are endemic in South America and elsewhere, and can lead to fetal malformations, neurological disease and death. Rather than providing protection, generation of cross-reactive antibodies against only one serotype of DENV can increase the severity... Read More

Highly Specific and Neutralizing Therapeutic Antibodies for Zika Virus

18-0023 – Our investigators have identified two highly specific and neutralizing antibodies isolated from a traveler naïve to all serotypes of Dengue. The antibodies (A9E and G9E) can be used against 7 different Zika virus types and react only to Zika virus and no other flaviviruses. Applications: •Diagnosis and treatment of Zika virus infection. •Antibody sequences for vaccine development. ... Read More

Conserved Epitopes for Vaccination Against GII.4 Norovirus Strains

17-0144 – Antigenic diversity within the GII.4 genotype of human norovirus is a significant hurdle to the development of cross-protective immunity after natural infection and vaccination. Our investigators have developed a method of identifying conserved GII.4 norovirus epitopes. Using this method, a conserved GII.4 antibody epitope and residues that mediate antibody access to this conserved epitope... Read More

Topical Tigecycline to Control Endodontic Infections

18-0031 – Endodontic infections result from a variety of bacteria and require treatment, which can include tooth extraction. The severity of infection can lead to hospital stay, morbidity, and even mortality, if not cared for properly. Though antibiotics are ideal, some bacteria have developed a resistance, as a result of antibiotic use in both medicine and dentisty. Tigecycline is a promising... Read More

Composition of a Polypeptide for the Synthesis of Heparan Sulfate

02-0105 – A novel isoform of 3-O-sulfotransferase that can be used for the synthesis of two separate forms of heparan sulfate (HS) has been discovered. Heparan sulfate can be isolated in many different isoforms that have unique properties and biological roles. The 3-O-sulfotranferase polypeptide sequence developed at UNC-Chapel Hill can be used to synthesize two separate types of HS: one form that can... Read More

Human African Trypanosomiasis (HAT) Compounds

16-0082 – Sleeping sickness or human African trypanosomiasis (HAT) is endemic in 37 African countries and around 13 million people are at medium to high risk of being infected. Sleeping sickness is transmitted by the tsetse fly and is usually fatal without treatment. It occurs in two stages; the early stage (stage 1) with non-specific symptoms, often un- or misdiagnosed - the late stage (stage 2)... Read More

Chimeric VLP for Vaccination Against G11.4 Norovirus Strains

13-0036 – A virus-like particle (VLP) has been developed in order to induce a more broadly blocking immune response against G11.4 strains of norovirus. This VLP contains multiple epitopes of different strains of norovirus in a backbone of a single strain, and consequently induces a more broadly blocking immune response than single strains alone. G11.4 noroviruses account for the majority of all... Read More

Recombinant Flavivirus (including Dengue and Zika) Quaternary Epitopes for Vaccines and Diagnostics

16-0047 – Dengue virus is the causative agent of dengue fever and dengue hemorrhagic fever, but there is currently no approved vaccine for the virus. Research at UNC has identified that a majority of the strongly neutralizing antibodies produced during dengue infection are targeted to the quaternary structure of the envelope E protein. However, since recombinant proteins are secreted as monomers, the... Read More